drugset / Trial / NCT03020524
Autologous CD4 T-Cells in HIV (C34-CXCR4)
Non-randomizedParallel-groupOpen-labelOther
Summary
A single cohort, open-label pilot study of the safety and tolerability of a single infusion of autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector in HIV-infected subjects. This is a first in human study of C34-CXCR4 T cells
Timeline
- Start
- 2017-01
- Primary completion
- 2019-11
- Completion
- 2020-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous CD4 T-Cells | Cell therapy | 8e+08 cells | Intravenous |
| Subject | Autologous CD4 T-Cells | Cell therapy | 2.4e+09 cells | Intravenous |
| Subject | Autologous CD4 T-Cells | Cell therapy | 8e+09 cells | Intravenous |